Ernexa Therapeutics (ERNAW) Shares Outstanding (Weighted Average) (2010 - 2026)

Ernexa Therapeutics has reported Shares Outstanding (Weighted Average) for 17 years, with the latest figure at $856611.0 in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) fell 46.76% year-over-year to $856611.0; the trailing twelve-month figure through Mar 2026 stood at $856611.0 (down 46.76% YoY), and the FY2025 full-year result was $6.3 million, up 593.08% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $856611.0, up from $16611.0 in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $6.9 million in Q1 2022, with the low at $4713.0 in Q1 2023.
• Historically, Shares Outstanding (Weighted Average) has averaged $2.1 million across 5 years, with a median of $1.3 million in 2023.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) soared 24566.35% — and 2023, when it slumped 99.93%.
• Ernexa Therapeutics' Shares Outstanding (Weighted Average) stood at $3.1 million in 2022, then slumped by 58.67% to $1.3 million in 2023, then declined by 27.84% to $910000.0 in 2024, then tumbled by 98.17% to $16611.0 in 2025, then surged by 5056.89% to $856611.0 in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $856611.0 (Q1 2026), $16611.0 (Q4 2025), and $415000.0 (Q3 2025), per Business Quant data.